Article
Oncology
Yasuyuki Ikezawa, Hidenori Mizugaki, Ryo Morita, Kazunari Tateishi, Keiki Yokoo, Toshiyuki Sumi, Hajime Kikuchi, Yasuo Kitamura, Atsushi Nakamura, Maki Kobayashi, Mari Aso, Nozomu Kimura, Fumiaki Yoshiike, Megumi Furuta, Hisashi Tanaka, Motoki Sekikawa, Tsutomu Hachiya, Keiichi Nakamura, Mototsugu Shimokawa, Satoshi Oizumi
Summary: This retrospective study compared the efficacy of pembrolizumab monotherapy (MONO) and pembrolizumab plus platinum-based chemotherapy (COMB) in advanced non-small-cell lung cancer with high PD-L1 expression. The results showed that COMB had better treatment outcomes and longer progression-free survival, and it may be a promising option for patients with high PD-L1 expression and good treatment response.
Article
Oncology
T. S. K. Mok, G. Lopes, B. C. Cho, D. M. Kowalski, K. Kasahara, Y. -l. Wu, G. de Castro Jr, H. Z. Turna, R. Cristescu, D. Aurora-Garg, A. Loboda, J. Lunceford, J. Kobie, M. Ayers, M. C. Pietanza, B. Piperdi, R. S. Herbst
Summary: This study evaluated the clinical utility of tissue tumor mutational burden (tTMB) and STK11, KEAP1, and KRAS mutations as biomarkers for pembrolizumab monotherapy versus platinum-based chemotherapy in PD-L1-positive advanced/metastatic non-small-cell lung cancer (NSCLC) patients. It suggests that tTMB could be a potential predictive biomarker for pembrolizumab monotherapy in NSCLC, and pembrolizumab is a standard first-line treatment regardless of STK11, KEAP1, or KRAS mutation status.
ANNALS OF ONCOLOGY
(2023)
Article
Immunology
Daniele Mengato, Luca Cancanelli, Melania Rivano, Marco Chiumente, Lorenzo Di Spazio, Andrea Messori
Summary: In PD-L1-negative advanced NSCLC patients, there is limited evidence supporting the efficacy of first-line chemoimmunotherapy compared to chemotherapy alone.
Article
Oncology
G. L. Banna, A. Cortellini, D. L. Cortinovis, M. Tiseo, J. G. J. Aerts, F. Barbieri, R. Giusti, E. Bria, F. Grossi, P. Pizzutilo, R. Berardi, A. Morabito, C. Genova, F. Mazzoni, V Di Noia, D. Signorelli, A. Gelibter, M. Macerelli, F. Rastelli, R. Chiari, D. Rocco, S. Gori, M. De Tursi, P. Di Marino, G. Mansueto, F. Zoratto, M. Filetti, M. Montrone, F. Citarella, R. Marco, L. Cantini, O. Nigro, E. D'Argento, S. Buti, G. Minuti, L. Landi, G. Guaitoli, G. Lo Russo, A. De Toma, C. Donisi, A. Friedlaender, A. De Giglio, G. Metro, G. Porzio, C. Ficorella, A. Addeo
Summary: This study focused on stratifying the prognosis of patients with PD-L1 >= 50% aNSCLC. It found that NLR < 4 was a significant prognostic factor and developed a risk model named lung immuno-oncology prognostic score (LIPS)-3 to accurately categorize patients into different risk levels for prognosis.
Article
Chemistry, Multidisciplinary
Zili Gu, Candido G. Da Silva, Yang Hao, Timo Schomann, Marcel G. M. Camps, K. van der Maaden, Qi Liu, Ferry Ossendorp, Luis J. Cruz
Summary: Therapeutic cancer drug efficacy is often limited by factors such as insufficient tumor penetration, rapid clearance, systemic toxicity, and drug resistance. In this study, a liposomal platform was used to improve the therapeutic index by enhancing drug penetration and reducing clearance and toxicity. The combination of docetaxel and pemetrexed encapsulated in pH-sensitive liposomes showed strong cytotoxicity and induced immunogenic cell death in cellular experiments. In vivo, the liposome-based drug combination inhibited tumor development and stimulated immune responses, with significantly reduced systemic toxicity. When combined with anti-PD-L1 immunotherapy, tumor control was further enhanced in mouse models of colon cancer. These findings highlight the promising potential of liposome-mediated chemotherapy combined with immunotherapy for the treatment of colon cancers.
JOURNAL OF CONTROLLED RELEASE
(2023)
Article
Oncology
Mohsin Shah, Melina E. Marmarelis, Ronac Mamtani, Sean Hennessy
Summary: This study found that among patients with advanced non-small cell lung cancer (aNSCLC) who received monotherapy with pembrolizumab as first-line treatment and had PD-L1 expression >50%, those with very high PD-L1 expression (>90%) had a lower risk of mortality and improved median survival compared to those with high PD-L1 expression (50%-89%).
CLINICAL LUNG CANCER
(2022)
Article
Oncology
Mohsin Shah, Ronac Mamtani, Melina E. Marmarelis, Sean Hennessy
Summary: In this cohort study, chemoimmunotherapy did not show an overall benefit over immunotherapy alone in the first-line treatment of advanced non-small cell lung cancer (aNSCLC). However, it did provide an early survival advantage in both the overall cohort and the subgroup of patients with a high PD-L1 expression (>90%). Future studies should focus on identifying higher risk patients who may benefit from the addition of chemotherapy.
CLINICAL LUNG CANCER
(2023)
Article
Engineering, Biomedical
Haihui Wang, Yongfei Liu, Xiaohui Zhu, Chengyun Chen, Zhangcheng Fu, Min Wang, Danying Lin, Zhaowei Chen, Chunhua Lu, Huanghao Yang
Summary: The study developed a multi-stage cooperative nanodrug PtR/CPG for antitumor chemoimmunotherapy by direct self-assembly of Pt, l-Arg, and CPG, triggering immunogenic cell death, enhancing antigen presentation, and reversing immunosuppressive microenvironment, leading to increased sensitivity of tumors to immune checkpoint inhibitors.
ADVANCED HEALTHCARE MATERIALS
(2021)
Article
Oncology
Martin Reck, Delvys Rodriguez-Abreu, Andrew G. Robinson, Rina Hui, Tibor Csoszi, Andrea Fulop, Maya Gottfried, Nir Peled, Ali Tafreshi, Sinead Cuffe, Mary O'Brien, Suman Rao, Katsuyuki Hotta, Ticiana A. Leal, Jonathan W. Riess, Erin Jensen, Bin Zhao, M. Catherine Pietanza, Julie R. Brahmer
Summary: This study reports the first 5-year follow-up of a first-line immunotherapy trial for NSCLC, demonstrating that pembrolizumab provides a durable, clinically meaningful long-term overall survival benefit in first-line treatment of metastatic NSCLC with a PD-L1 tumor proportion score of at least 50%.
JOURNAL OF CLINICAL ONCOLOGY
(2021)
Article
Oncology
Oladimeji Akinboro, Erin Larkins, Lee H. Pai-Scherf, Luckson N. Mathieu, Yi Ren, Joyce Cheng, Mallorie H. Fiero, Wentao Fu, Youwei Bi, Shyam Kalavar, Samina Jafri, Pallavi S. Mishra-Kalyani, Jeanne Fourie Zirkelbach, Hongshan Li, Hong Zhao, Kun He, Whitney S. Helms, Meredith K. Chuk, Min Wang, Ilynn Bulatao, Jonathan Herz, Blaire L. Osborn, Yuan Xu, Jiang Liu, Yutao Gong, Sharon Sickafuse, Rebecca Cohen, Martha Donoghue, Richard Pazdur, Julia A. Beaver, Harpreet Singh
Summary: The FDA's approval of cemiplimab-rwlc as a first-line treatment for PD-L1-positive advanced non-small cell lung cancer (NSCLC) is supported by significant improvements in overall survival in international clinical trials. These single-agent anti-PD-L1 antibodies have demonstrated comparable efficacy and manageable safety profiles.
CLINICAL CANCER RESEARCH
(2022)
Article
Oncology
Helene Doubre, Laurent Greillier, Gregoire Justeau, Charles Ricordel, Aurelie Swalduz, Hubert Curcio, Olivier Bylicki, Jean-Bernard Auliac, Florian Guisier, Laurence Bigay-Game, Marie Bernardi, Julian Pinsolle, Karim Amrane, Chantal Decroisette, Renaud Descourt, Christos Chouaid, Margaux Geier
Summary: This study analyzed the impact and characteristics of venous thrombotic events (VTE) in patients with metastatic non-small cell lung cancer (mNSCLC) receiving immunotherapy. The results showed that the incidence of VTE was 14.8%, and patients with VTE had shorter progression-free survival (PFS) but no significant impact on overall survival (OS) in multivariate analysis.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2023)
Article
Oncology
Helene Doubre, Laurent Greillier, Gregoire Justeau, Charles Ricordel, Aurelie Swalduz, Hubert Curcio, Olivier Bylicki, Jean-Bernard Auliac, Florian Guisier, Laurence Bigay-Game, Marie Bernardi, Julian Pinsolle, Karim Amrane, Chantal Decroisette, Renaud Descourt, Christos Chouaid, Margaux Geier
Summary: Limited data are available on the impact of venous thrombotic events (VTE) in patients with metastatic non-small cell lung cancer (mNSCLC) treated with immunotherapy. This study analyzed the incidence of VTE and its influence on patient characteristics and outcomes in a cohort of mNSCLC patients receiving first-line treatment with pembrolizumab monotherapy. The results showed a relatively high incidence of VTE in these patients, with younger age, long-term corticosteroid treatment, and liver metastases being associated with higher risk. The occurrence of VTE was found to significantly reduce progression-free survival (PFS), but did not have a significant impact on overall survival (OS).
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2023)
Article
Immunology
Shubin Chen, Haowen Wei, Wenhua Zhao, Wei Jiang, Ruiling Ning, Shaozhang Zhou, Liping Tan, Huilin Wang, Cuiyun Su, Jianbo He, Aiping Zeng, Yun Zhao, Qitao Yu
Summary: The study found that PD-1/PD-L1 inhibitors plus anti-angiogenic agents with or without chemotherapy were more effective and safe than PD-1/PD-L1 inhibitors plus chemotherapy as second or later-line treatment for patients with advanced non-small cell lung cancer.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Materials Science, Multidisciplinary
Haihui Wang, Xiaohui Zhu, Han Xiao, Yongfei Liu, Zhangcheng Fu, Yihang Ding, Chunsen Li, Chunhua Lu, Xiankun Tu
Summary: We developed an immunostimulatory nanosphere that promotes the antigen presentation ability of mature dendritic cells (DCs) and reverses tumor immune suppression by downregulating regulatory T cell levels and inducing immunogenic cell death. When combined with PD-L1 antibody, it decreases exhaustion of cytotoxic T lymphocytes and elicits durable systemic anti-tumor immunity.
MATERIALS & DESIGN
(2022)
Article
Medicine, General & Internal
Dolores Isla, Alfredo Sanchez, Joaquin Casal, Manuel Cobo, Margarita Majem, Noemi Reguart, Jon Zugazagoitia, Reyes Bernabe
Summary: This manuscript evaluates the available data and results of pivotal trials of atezolizumab, cemiplimab, and pembrolizumab as monotherapy in advanced non-small cell lung cancer patients with high PD-L1 expression. It also considers the differences among these drugs in terms of treatment decision-making.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Oncology
Kenji Morimoto, Junji Uchino, Takashi Yokoi, Takashi Kijima, Yasuhiro Goto, Akira Nakao, Makoto Hibino, Takayuki Takeda, Hiroyuki Yamaguchi, Chieko Takumi, Masafumi Takeshita, Yusuke Chihara, Takahiro Yamada, Osamu Hiranuma, Yoshie Morimoto, Masahiro Iwasaku, Yoshiko Kaneko, Tadaaki Yamada, Koichi Takayama
Summary: The study found that for NSCLC patients receiving chemoimmunotherapy, completing less than four courses of induction chemotherapy due to adverse events resulted in significantly shorter progression-free survival (PFS) compared to those who completed at least four courses. However, there was no significant difference in PFS between patients whose induction chemotherapy ended in two to three courses with partial or complete response and those who continued with at least four courses of induction chemotherapy.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2022)
Article
Oncology
Keiko Tanimura, Tadaaki Yamada, Koutaroh Okada, Kunihiro Nakai, Mano Horinaka, Yuki Katayama, Kenji Morimoto, Yuri Ogura, Takayuki Takeda, Shinsuke Shiotsu, Kosuke Ichikawa, Satoshi Watanabe, Yoshie Morimoto, Masahiro Iwasaku, Yoshiko Kaneko, Junji Uchino, Hirokazu Taniguchi, Kazue Yoneda, Satoaki Matoba, Toshiyuki Sakai, Hisanori Uehara, Seiji Yano, Tetsuro Kusaba, Ryohei Katayama, Koichi Takayama
Summary: This study elucidates the pivotal role of HER3 activation in the emergence of drug-tolerant cells in ALK-rearranged lung cancer, and finds that inhibiting HER3 signals combined with ALK-TKI treatment dramatically improves outcomes in ALK-rearranged lung cancer with mesenchymal features.
NPJ PRECISION ONCOLOGY
(2022)
Article
Oncology
Yohei Matsui, Tadaaki Yamada, Kenji Morimoto, Yuki Katayama, Osamu Hiranuma, Shinsuke Shiotsu, Nobuyo Tamiya, Takayuki Takeda, Yoshie Morimoto, Masahiro Iwasaku, Shinsaku Tokuda, Koichi Takayama
Summary: Treatment with PTX or nab-PTX is effective and well-tolerated for patients with relapsed SCLC, including those with interstitial lung disease. Pretreatment inflammatory and nutritional indices may serve as useful biomarkers for predicting treatment outcomes.
ANTICANCER RESEARCH
(2022)
Article
Oncology
Hirokazu Taniguchi, Kazumasa Akagi, Yosuke Dotsu, Tadaaki Yamada, Sawana Ono, Erika Imamura, Hiroshi Gyotoku, Shinnosuke Takemoto, Hiroyuki Yamaguchi, Triparna Sen, Seiji Yano, Hiroshi Mukae
Summary: This study investigated the molecular mechanisms of acquired resistance to lorlatinib in ALK-rearranged lung cancer cells. It was found that the resistant cells did not harbor secondary ALK mutations, but overexpressed HER3 protein and NRG1 ligand. Inhibiting HER3 or silencing HER3 gene resensitized the resistant cells to lorlatinib. Targeting NRG1/HER3 may be a potential novel therapeutic option for lorlatinib-resistant ALK-rearranged lung cancer.
Article
Oncology
Akihiro Yoshimura, Tadaaki Yamada, Masakuni Serizawa, Hisanori Uehara, Keiko Tanimura, Yusuke Okuma, Akito Fukuda, Satoshi Watanabe, Naoya Nishioka, Takayuki Takeda, Yusuke Chihara, Shinnosuke Takemoto, Taishi Harada, Osamu Hiranuma, Yukina Shirai, Takehito Shukuya, Akihiro Nishiyama, Yasuhiro Goto, Shinsuke Shiotsu, Kei Kunimasa, Kenji Morimoto, Yuki Katayama, Kenichi Suda, Tetsuya Mitsudomi, Seiji Yano, Hirotsugu Kenmotsu, Toshiaki Takahashi, Koichi Takayama
Summary: This study investigated the impact of drug tolerant-related protein expression in tumors on the efficacy of osimertinib in treating EGFR-mutated NSCLC patients. The results show that high levels of AXL expression in tumors significantly impact clinical predictions when using osimertinib to treat EGFR-mutated NSCLC patients.
Article
Oncology
Ryota Nakamura, Tadaaki Yamada, Satomi Tanaka, Aosa Sasada, Shinsuke Shiotsu, Nozomi Tani, Takayuki Takeda, Yusuke Chihara, Soichi Hirai, Yoshizumi Takemura, Akihiro Yoshimura, Kenji Morimoto, Masahiro Iwasaku, Shinsaku Tokuda, Young Hak Kim, Koichi Takayama
Summary: This retrospective study found that symptomatic cerebral infarction or pulmonary embolism in non-small cell lung cancer patients may be associated with poor prognosis. The study also suggested that patients with symptomatic cerebral infarction may have worse prognosis compared to those with pulmonary embolism. High levels of D-dimer may serve as a promising indicator for predicting clinical outcomes in non-small cell lung cancer patients with symptomatic cerebral infarction.
Article
Oncology
Yuki Katayama, Tadaaki Yamada, Keiko Tanimura, Shinsaku Tokuda, Kenji Morimoto, Soichi Hirai, Yohei Matsui, Ryota Nakamura, Masaki Ishida, Hayato Kawachi, Kazue Yoneda, Kazutaka Hosoya, Takahiro Tsuji, Hiroaki Ozasa, Akihiro Yoshimura, Masahiro Iwasaku, Young Hak Kim, Mano Horinaka, Toshiyuki Sakai, Takahiro Utsumi, Shinsuke Shiotsu, Takayuki Takeda, Ryohei Katayama, Koichi Takayama
Summary: In this study, it was found that epidermal growth factor receptor (EGFR) signaling is involved in adaptive resistance to lorlatinib in ALK-rearranged NSCLC. EGFR inhibition enhanced ALK inhibition-induced apoptosis and halted the proliferation of ALK-rearranged lung cancer cells. Combination therapy with EGFR inhibitor and lorlatinib significantly suppressed tumor regrowth after cessation of treatment. This study provides new insights into tumor evolution and the development of combined therapeutic strategies for ALK-rearranged lung cancer.
NPJ PRECISION ONCOLOGY
(2023)
Article
Geriatrics & Gerontology
Kenji Morimoto, Tadaaki Yamada, Takayuki Takeda, Shinsuke Shiotsu, Koji Date, Taishi Harada, Nobuyo Tamiya, Yusuke Chihara, Yoshizumi Takemura, Takahiro Yamada, Hibiki Kanda, Masaki Ishida, Akihiro Yoshimura, Masahiro Iwasaku, Shinsaku Tokuda, Young Hak Kim, Koichi Takayama
Summary: This study aimed to investigate the role of the Geriatric 8 (G8) screening tool in evaluating treatment outcomes in patients with small cell lung cancer (SCLC) treated with PD-L1 inhibitors and platinum-etoposide chemotherapy. The results showed that a G8 score > 11 was associated with longer overall survival in patients with extensive-stage SCLC, and it could serve as an independent prognostic factor. Especially in patients with good performance status, those with a higher G8 score had a significantly longer survival period.
Article
Oncology
Takayuki Takeda, Tadaaki Yamada, Yusuke Kunimatsu, Keiko Tanimura, Kenji Morimoto, Shinsuke Shiotsu, Yusuke Chihara, Asuka Okada, Shigeto Horiuchi, Makoto Hibino, Kiyoaki Uryu, Ryoichi Honda, Yuta Yamanaka, Hiroshige Yoshioka, Takayasu Kurata, Koichi Takayama
Summary: Chemoimmunotherapy was found to improve overall survival (OS) and progression-free survival (PFS) in patients with extensive-stage small cell lung cancer (ES-SCLC) in previous phase III trials. However, the efficacy and safety of this treatment in elderly patients aged 75 years and older in Japan need to be evaluated using real-world evidence. A study evaluated 225 Japanese patients with SCLC, with 155 receiving chemoimmunotherapy. The study found that the dose reduction at the initiation of the first cycle was higher in elderly patients and that there were no significant differences in PFS and OS between non-elderly and elderly patients.
Article
Oncology
Kenji Morimoto, Tadaaki Yamada, Takayuki Takeda, Shinsuke Shiotsu, Koji Date, Nobuyo Tamiya, Yasuhiro Goto, Hibiki Kanda, Yusuke Chihara, Yusuke Kunimatsu, Yuki Katayama, Masahiro Iwasaku, Shinsaku Tokuda, Koichi Takayama
Summary: This study aimed to evaluate the efficacy and safety of first-generation and second-generation EGFR tyrosine kinase inhibitors (TKIs) after the development of osimertinib resistance. The results showed limited efficacy of first-generation and second-generation EGFR-TKIs in patients with EGFR-mutant NSCLC. Additionally, normal CYFRA 21-1 and ProGRP levels could be promising indicators for the administration of first-generation and second-generation EGFR-TKIs after osimertinib resistance development.
Article
Oncology
Keiko Tanimura, Takayuki Takeda, Akihiro Yoshimura, Ryoichi Honda, Shiho Goda, Shinsuke Shiotsu, Mototaka Fukui, Yusuke Chihara, Kiyoaki Uryu, Shota Takei, Yuki Katayama, Makoto Hibino, Tadaaki Yamada, Koichi Takayama
Summary: A prognostic risk classification combining pre-chemoradiotherapy (CRT) modified Glasgow Prognostic Score (mGPS) and post-CRT C-reactive protein (CRP) level helps predict progression-free survival (PFS) and overall survival (OS) of durvalumab consolidation after CRT in locally advanced non-small cell lung cancer (NSCLC) patients.
Article
Oncology
Keiko Tanimura, Takayuki Takeda, Nobutaka Kataoka, Akihiro Yoshimura, Kentaro Nakanishi, Yuta Yamanaka, Hiroshige Yoshioka, Ryoichi Honda, Kiyoaki Uryu, Mototaka Fukui, Yusuke Chihara, Shota Takei, Hayato Kawachi, Tadaaki Yamada, Nobuyo Tamiya, Naoko Okura, Takahiro Yamada, Junji Murai, Shinsuke Shiotsu, Takayasu Kurata, Koichi Takayama
Summary: This study found that first-line chemoimmunotherapy significantly improved overall survival and progression-free survival in patients with non-small cell lung cancer who had PD-L1 expression within the range of 1-49%. However, the benefits of chemoimmunotherapy were limited for patients with PD-L1 expression less than 1%.
Article
Oncology
Hayato Kawachi, Tadaaki Yamada, Akihiro Yoshimura, Kenji Morimoto, Masahiro Iwasaku, Shinsaku Tokuda, Young Hak Kim, Takayuki Shimose, Koichi Takayama
Summary: This study aims to evaluate the clinical efficacy of combining erlotinib and ramucirumab for the treatment of treatment-naive EGFR mutation-positive NSCLC with high PD-L1 expression.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY
(2023)
Article
Oncology
Tadaaki Yamada, Yasuhiro Goto, Hiroshi Tanaka, Hideharu Kimura, Koichi Minato, Hiroshi Gyotoku, Takeshi Honda, Satoshi Watanabe, Kenji Morimoto, Fumiaki Kiyomi, Junji Uchino, Koichi Takayama
Summary: This study evaluated the efficacy and safety of durvalumab after radiation monotherapy for stage III NSCLC patients who are ineligible for chemoradiotherapy. The results showed that durvalumab is an effective and tolerable treatment option, although the occurrence of radiation pneumonitis is relatively high.
EUROPEAN JOURNAL OF CANCER
(2023)